Obstetric outcomes and acceptance of alternative therapies to blood transfusion by Jehovah’s Witnesses in Japan: a single-center study
We sought to investigate obstetric outcomes and acceptance rates for blood products or types of autotransfusion by Jehovah’s Witnesses (JWs) at a single institution in Japan. We retrospectively reviewed cases of 84 pregnant JW patients and 95 deliveries from April 2001 to August 2017. We examined the acceptance rates of blood transfusions, blood products, and autotransfusion types in patients who experienced postpartum hemorrhage (PPH), and investigated estimated hemorrhage volume at delivery and PPH treatments. Of the 84 JW patients, none accepted blood transfusion; however, 75 patients (89.3%) accepted blood products, 57 (67.9%) accepted autotransfusion using intraoperative cell salvage, and four (4.8%) refused all alternatives to blood transfusion. Furthermore, PPH > 1000 mL occurred in 18 of the 95 (18.9%) deliveries. Of these 18 patients, four (22.2%) required blood products and three (16.7%) required supracervical hysterectomy to control PPH. No maternal deaths occurred. Approximately 95% of the patients observed accepted all or some alternatives to blood transfusion. To treat JW patients in a safer manner, understanding their individual acceptance of alternatives to blood transfusion is important for the strategic use of such alternatives.
KeywordsJehovah’s Witnesses Blood products Autotransfusion Obstetric outcomes Cell salvage
The authors thank H. Abe and K. Sakiyama for their administrative assistance in preparing this manuscript.
MT, SM, and EM made substantial contributions to the conception and design of this manuscript, collected the clinical data, and drafted as well as revised the manuscript. KM, TTu, TTa, and TK helped in drafting the manuscript and responded to the submission requirements. TK conceived and generally supervised this study, and gave final approval for the publication of this manuscript. All the authors have read and approved the final manuscript.
There is no source of financial support or funding.
Compliance with ethical standards
Conflict of interest
The authors declare no conflicts of interest or relevant financial relationships related to this study.
- 2.jw. http://www.jw.org/ja/. Accessed 17 Aug 2017
- 17.Shirahata A, Kamiya T, Takamatsu J, Kojima T, Fukutake K, Arai M, et al. Clinical trial to investigate the pharmacokinetics, pharmacodynamics, safety, and efficacy of recombinant factor VIIa in Japanese patients with hemophilia with inhibitors. Int J Hematol. 2001;73:517–25.CrossRefPubMedGoogle Scholar